LIN BIOSCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 93.1 TWD | +18.90% |
|
+25.81% | -18.33% |
| 23/04 | Lin BioScience, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Lin BioScience, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 8.95B 291B 746B |
|---|---|---|---|---|---|
| Net income 2022 | -314M -10.23B -26.18B | Net income 2023 | -687M -22.38B -57.28B | EV / Sales 2022 | - |
| Net cash position 2022 | 1.6B 52.09B 133B | Net cash position 2023 | 3.22B 105B 268B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-39.8
x | P/E ratio 2023 |
-12.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
| 1 day | +18.90% | ||
| 1 week | +25.81% | ||
| Current month | +5.80% | ||
| 1 month | -4.71% | ||
| 3 months | -11.33% | ||
| 6 months | -20.77% | ||
| Current year | -18.33% |
1 week
70.50
93.90
1 month
70.0095.30
Current year
70.00117.50
1 year
70.00174.50
3 years
70.00273.00
5 years
27.00301.00
10 years
27.00301.00
| Managers | Title | Age | Since |
|---|---|---|---|
Yue Hsin Lin
FOU | Founder | 46 | 12/16/12 |
Wan Shan Chen
DFI | Director of Finance/CFO | 38 | 01/16/01 |
Hung Wei Chen
COO | Chief Operating Officer | 43 | 01/16/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hsien Hua Huang
BRD | Director/Board Member | - | 27/18/27 |
San Chien Tu
BRD | Director/Board Member | - | 27/18/27 |
Chan Yue Li
BRD | Director/Board Member | 52 | 13/16/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 93.1 | +18.90% | 1,103,235 |
| 25/24/25 | 78.3 | +3.03% | 265,668 |
| 24/24/24 | 76 | +3.83% | 361,887 |
| 23/24/23 | 73.2 | +1.67% | 316,648 |
| 22/24/22 | 72 | -2.70% | 352,877 |
End-of-day quote Taipei Exchange, April 26, 2024
More quotes
LIN BIOSCIENCE, INC. is a Taiwan-based company mainly engaged in the development of new pharmaceutical drugs. The Company is in the research and development and clinical trials stage. It has four major drugs in development, including LBS-008, LBS-007, LBS-009 and LBS-002, as well as two technical platforms of RBP4 and CDC7. LBS-008 is developed for dry macular degeneration which belongs to the best-selling drugs, and stel lesions which belongs to orphan drugs. LBS-007 is used in acute leukemia which belongs to orphan drugs, and solid tumors which belongs to the best-selling drugs. LBS-009 is used in non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) and type 2 diabetes. LBS-002 is developed for primary brain cancer and metastatic brain cancer. RBP4 platform is used for metabolic diseases, and CDC7 platform is used for all cancers.
Sector
Pharmaceuticals
| 1st Jan change | Capi. | |
|---|---|---|
| -18.33% | 224M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 6696 Stock
